A Database Study to evaluate the Effect of Cancer Cachexia (Weight loss) on Anti-Cancer Drug in Patients with Pancreatic Cancer who receive the first line Chemotherapy
- Conditions
- Pancreatic Cancer
- Registration Number
- JPRN-UMIN000045820
- Lead Sponsor
- Ono Pharmaceutical Co., Ltd.
- Brief Summary
Cancer cachexia was tended to be associated with shorter TTF and reduced number of doses in patients with pancreatic cancer who received first-line chemotherapy
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1897
Not provided
Pancreatic cancer stage < 3 on the first day of initial chemotherapy Patients who received initial chemotherapy < 60 days followed by surgery Patients who have undergone surgery for pancreatic cancer between the most recent diagnosis of pancreatic cancer and the start of initial chemotherapy. Relapsed patients without initial surgery Relapsed patients without initial information Relapsed patients without initial postoperative chemotherapy Recurrence less than 183 days after completion of initial postoperative chemotherapy Patients with recurrent pancreatic cancer of stage 3 or higher at the initial onset who have received preoperative chemotherapy for at least 60 days
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Presence/absence of discontinuation/completion of initial chemotherapy (1st line) and number of days until that
- Secondary Outcome Measures
Name Time Method Presence/absence of discontinuation/completion of initial chemotherapy (1st line) and the number of drug prescriptions before that Overall Survival (OS) etc